Preventing COVID-19 in at-risk populations: moving towards next-generation mRNA-1283 COVID-19 vaccine to address current challenges.

Phase 1-3 clinical trials demonstrated that mRNA-1283 was well-tolerated, with safety and reactogenicity profiles comparable to mRNA-1273. Furthermore, mRNA-1283 demonstrated higher point estimates of immunogenicity and relative vaccine efficacy than mRNA-1273, including among older adults and individuals with underlying conditions who are most susceptible to severe COVID-19. Initial modeling studies indicate that mRNA-1283 could prevent more hospitalizations than current COVID-19 vaccines. Evidence to date suggests that the novel next-generation mRNA-1283 vaccine holds promise to advance progress in reducing the ongoing burden of COVID-19 across vulnerable populations.